Connect with us


Western Government Sees Iran’s Economy Imploding Quickly



Western officials believe that Iran’s economy is crashing so quickly that it has the potential to merge the next spring under the collapsed pressure of oil embargo, international sanctions, and internal negligence by governments in Tehran.

The government officials in West predicts that Iran will be given all the foreign trade reserves and there won’t be any changes made to the policy for another 6 months or a year, making it unfeasible for the Islamic government to export their items foreign. In order to buy the imported things, Islamic Republic will have to run its public services and manufacturing sector, said by one of the European diplomats.

Western officials have made their policies very strict this time on Iran in the hope to cripple the trades. The tightened economic sanctions set off an monetary crisis, which will force heads in Tehran to abandon or curb a nuclear program, which the Western government fears is planned at constructing a nuclear bomb. The capital ofIran,Tehranhas stayed rebellious, claiming that it’s uranium enrichment process for peaceful purposes.  Officials of West believe that enriching uranium at the full scale might cause imbalance payment and threaten the government’s survival, sparking domestic unrest.

The European Union made changes in its policy, adding a new sanction onIran’s financial, energy, and natural resources divisions. The changes likely to imbalanceIran’s foreign exchange reserves further and speed up the plunge in the assets of its currency. The new sanctions cut offIran’s oil exports by half and limited its ability to conduct global financial transactions, told by a diplomat, who spoke to the media regarding the inscrutability or secrecy due to the diplomatic sensitivity of the issue.

West has been waiting for the moment whenIran’s foreign currency reserves will run low, as they want to force the nation to give up its nuclear program before it starts enriching enough uranium and start working on building a warhead. If everything happens accordingly,Israel’s government believes that time to come next spring, but Barack Obama’s government says it may be several years off.

Other Western officials have kept mum and may come up with their thoughts whenIranwill reach the crisis point. The executive director of Democracies Mark Dubowitz said that economy condense needs to occur beforeIranreaches its goal. The meltdown should happen at least 6 months prior toIran’s nuclear development. Cliff Kupchan, one of the analysts said that it’s quite hard to predict when Iran’s economy will be turned down and hence, it is better to come up with new and complex factors to analyze things in a better way.

Continue Reading


Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)




Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading


Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)



Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading


Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)



Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading